Company Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Ram Aiyar |
Contact Details
Address: One Kendall Square, Building 600-700 Cambridge, Massachusetts 02139 United States | |
| Phone | 617 468 1999 |
| Website | korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer and Director |
| Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Olukemi A. Olugemo M.D. | Advisor |
| Dr. Andrew Fraley Ph.D. | Co-Founder and Advisor |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder and Advisor |
| Todd Chappell M.B.A. | Chief Operating Officer |
| Oliver Dolan | Senior Vice President of Finance and Principal Accounting Officer |
| Dr. Loic Vincent Ph.D. | Chief Scientific Officer |
| Stephanie Engels | Chief People Officer |
| Dr. Venkat Krishnamurthy Ph.D. | Senior Vice President and Head of Platform |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Oct 8, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K/A | [Amend] Current report |